EUCTR2006-000063-28-DE进行中（未招募）不适用
A monocentric, double-blind, randomized phase III clinical study to investigate the antimicrobial efficacy and local tolerability of an antiseptic (Stellisept mucosa, containing 0.1 % octenidine dihydrochloride) after a single application at the genital mucosa in comparison to a reference product (Octenisept®) in a panel of 44 healthy male and female volunteer
BODE Chemie GmbH0 个研究点目标入组 44 人开始时间: 2006年3月3日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 44
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- male and female healthy volunteers
- •- 18-65 years of age
- •- informed consent
- •- negative pregnancy test
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- age under 18 or over 65
- •- pregnancy or lactating mother
研究者
相似试验
未知
3 期
A randomized-controlled, double-blinded, phase III study of CS-866AZEssential hypertensionJPRN-jRCT2080220281DAIICHISANKYO Co.,Ltd.
已完成
3 期
OM-85 in the prevention of asthma in high-risk childreAsthmaRespiratory - AsthmaInflammatory and Immune System - Normal development and function of the immune systemACTRN12612000518864Child Health Research Centre, University of Queensland60
进行中（未招募）
1 期
A randomized Phase III clinical trial to compare the efficacy and safety of the biosimilar rituximab GP2013 in combination with a standard chemotherapy (CVP) or rituximab MabThera in combination with a standard chemotherapy (CVP), including GP2013/MabThera maintenance therapy in patient with previously untreated advanced stage follicular lymphoma.Advanced stage follicular lymphoma.MedDRA version: 20.0 Level: PT Classification code 10016910 Term: Follicle centre lymphoma, follicular grade I, II, III stage IV System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10016909 Term: Follicle centre lymphoma, follicular grade I, II, III stage III System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-019522-13-IEHEXAL AG (a Sandoz company)627
进行中（未招募）
1 期
A randomized Phase III clinical trial to compare the efficacy and safety of the biosimilar rituximab GP2013 in combination with a standard chemotherapy (CVP) or rituximab MabThera in combination with a standard chemotherapy (CVP), including GP2013/MabThera maintenance therapy in patient with previously untreated advanced stage follicular lymphoma.EUCTR2010-019522-13-FRHEXAL AG (a Sandoz company)618
进行中（未招募）
1 期
A randomized Phase III clinical trial to compare the efficacy and safety of the biosimilar rituximab GP2013 in combination with a standard chemotherapy (CVP) or rituximab MabThera in combination with a standard chemotherapy (CVP), including GP2013/MabThera maintenance therapy in patient with previously untreated advanced stage follicular lymphoma.Advanced stage follicular lymphoma.MedDRA version: 14.1Level: PTClassification code 10016910Term: Follicle centre lymphoma, follicular grade I, II, III stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10016909Term: Follicle centre lymphoma, follicular grade I, II, III stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-019522-13-GRHEXAL AG (a Sandoz company)618